Answers are grounded in this paper and cite their sources.
The effective absorption of oral chemotherapy drugs in the intestines is of vital importance for enhancing their therapeutic effects. Natural plant-derived compounds, in specific, their diversities in type, structure, and function, might offer opportunities to modulate gut microbiota metabolites for enhancing colorectal cancer therapy. Guided by this thinking, synergistic self-assembly of natural products, namely Xyl-CA/Sin nanoparticles (NPs), was engineered by integrating the prebiotic xylan (Xyl) with chlorogenic acid (CA) and sinomenine (Sin). Xyl protects the formulation during gastric transit and promotes targeted accumulation in colorectal tumors. Upon exposure to the acidic tumor microenvironment (TME), the NPs release CA and Sin, enabling their therapeutic actions. In colorectal cancer (CRC) models, CA triggers tumor cell pyroptosis, while Sin reshapes macrophage polarization and elevates the microbial tryptophan metabolite indole-3-acetic acid (3-IAA). Acting synergistically, 3-IAA and CA suppress glutathione peroxidase 3 (GPx3) and glutathione peroxidase 7 (GPx7), leading to reactive oxygen species (ROS) accumulation and autophagy inhibition. This cascade restrains tumor growth, induces immunogenic cell death (ICD), and stimulates antitumor immunity. Overall, this study presents a microbiota metabolite-driven strategy through the application of natural plant-derived bioactive compounds to potentiate chemotherapy and establishes a concise, multimodal framework for antitumor therapy based on natural products.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: